| IMS
HEALTH data from its annual World
Review report shows that audited global pharmaceutical
sales grew 10% at a constant dollar rate in 2000,
to reach $317.2 billion - up from $295.9 billion
in 1999.
IMS HEALTH's World Review tracks actual sales
of approximately 90% of all prescription drugs and
certain over-the-counter (OTC) products in more than
60 countries. Proprietary data projection methodologies
are used to estimate total global pharmaceutical sales,
which grew to $354 billion in 2000.
"The global pharmaceutical industry experienced solid
growth in 2000, although growth rates vary greatly
from region to region," said Graham Lewis, IMS HEALTH
vice president, strategic consulting.
"North
America is by far the most dynamic pharmaceutical
market in the world, with 14% growth in
2000. We expect overall strong growth to continue
in view of the many innovative compounds under development,
and the increasing speed of worldwide product launches."
World Review is compiled using IMS HEALTH's
MIDAS
global analysis system, which captures pharmaceutical
activity from more than 60 countries. Growth in sales
is measured in local currencies enabling analyses
without the influence of fluctuating currency exchange
rates. Pharmaceutical sales figures include prescription
and certain OTC data, and represent manufacturer prices.
Leading regions
North
America, Europe and Japan accounted for more than
88% of worldwide pharmaceutical consumption in 2000.
| Global
pharmaceutical sales in 2000 by region
| World
Audited Market |
2000
Sales (US$Bn) |
%
Global Sales |
%
Growth Year-over-Year* |
| North
America |
152.8
|
48.2%
|
14% |
| Europe
|
75.3
|
23.7
|
8 |
| Japan
|
51.5
|
16.2
|
3 |
| Latin
America |
18.9
|
6.0
|
9 |
| Asia,
Africa and Australia |
18.7
|
5.9
|
10 |
| TOTAL
|
$317.2
|
100%
|
10% |
|
Source:
World Review 2001 (*Growth measured in constant US
dollars)
Sales cover direct and indirect pharmaceutical channel
purchases from pharmaceutical wholesalers and manufacturers.
Figures include prescription and certain OTC data,
exclude US home healthcare sales, and represent manufacturer
prices.
North American pharmaceutical sales grew 14% to $152.8
billion, representing more than 48% of total global
pharmaceutical sales in 2000. Europe also showed
solid growth of 8% to $75.3 billion, becoming the
world's second-largest pharmaceutical market. Japan
is now the third-largest market, experiencing moderate
year-over-year growth of 3%.
Strong growth opportunities are reflected in the 9%
increase in Latin
American pharmaceutical sales in 2000, and 10%
pharmaceutical growth in Asia
(excluding Japan), Africa and Australia.
Leading therapy classes
The top ten therapy classes accounted for 31% of the
total world market in 2000. Four out of the leading
ten - cholesterol
and triglyceride reducers, antirheumatic non-steroidals,
antipsychotics
and oral antidiabetics - grew more than 20% year-over-year.
The antiulcerant class totaled $17.4 billion
in sales in 2000, and remains the leading therapeutic
class worldwide, as it has for the past ten years.
Representing 5.5% of all audited global pharmaceutical
sales, antiulcerant sales were up 13% from 1999. AstraZeneca's
Losec/Prilosec (omeprazole), the world's
leading antiulcerant product and number one selling
drug, accounted for $6.1 billion, or 35%, of all sales
in this class.
Cholesterol and triglyceride reducers grew 21%, placing
the class second in sales rankings. Antidepressants,
the third-ranked therapy class, experienced 18% sales
growth in 2000, to $13.4 billion in annual sales.
| Leading
therapy classes in 2000 global pharmaceutical
sales
| Rank
|
Audited
World Therapy Class |
2000
Sales (US$Bn) |
%
Global Sales |
%
Growth Year-over-Year* |
| 1
|
Antiulcerants
|
17.4
|
5.5%
|
13% |
| 2
|
Cholest
& Triglyceride Reducers |
15.9
|
5.0
|
21 |
| 3
|
Antidepressants
|
13.4
|
4.2
|
18 |
| 4
|
Calcium
Antagonists, Plain |
9.8
|
3.1
|
2 |
| 5
|
Antirheumatic
Non-Steroidals |
9.5
|
3.0
|
26 |
| 6
|
ACE
Inhibitors, Plain |
7.3
|
2.3
|
3 |
| 7
|
Cephalosporins
& Combinations |
6.9
|
2.2
|
-5 |
| 8
|
Antipsychotics
|
6.0
|
1.9
|
22 |
| 9
|
Non-Narcotic
Analgesics |
6.0
|
1.9
|
3 |
| 10
|
Oral
Antidiabetics |
5.9
|
1.9
|
26 |
|
|
Total
Leading 10 ATCs at Level 3 |
$98.2
|
31.0%
|
+13% |
|
Source: World Review 2001 (*Growth measured in constant
US dollars)
Leading products
Within the total audited world market, Losec/Prilosec
is the top-selling drug, with $6.1 billion in 2000
sales and 9% growth. Pfizer's cholesterol drug Lipitor,
ranked number two, experienced the largest year-over-year
growth in sales, totaling $5.4 billion in 2000, a
44% increase. Merck & Co's cholesterol-lowering drug
Zocor is ranked third, with $4.4 billion in
sales and 15% growth.
Of the top 10 best-selling drugs in 2000, the fastest-growing
product worldwide was Pharmacia Corporation's Celebrex,
which treats adult osteoarthritis and was launched
in early 1999 in collaboration with Pfizer. Celebrex
generated $2.4 billion in sales in 2000, up 65% from
1999.
| Global
pharmaceutical sales in 2000 - leading products
| Rank
|
Audited
World Product Sales |
2000
Sales (US$Bn) |
%
Global Sales |
%
Growth Year-over-Year |
| 1
|
Losec/Prilosec
|
6.1
|
1.9%
|
9% |
| 2
|
Lipitor
|
5.4
|
1.7
|
44% |
| 3
|
Zocor
|
4.4
|
1.4
|
15% |
| 4
|
Norvasc
|
3.3
|
1.1
|
15% |
| 5
|
Ogastro/Prevacid
|
3.1
|
1.0
|
33% |
| 6
|
Prozac
|
2.9
|
0.9
|
-1% |
| 7
|
Seroxat/Paxil
|
2.4
|
0.8
|
20% |
| 8
|
Zyprexa
|
2.4
|
0.8
|
30% |
| 9
|
Celebrex
|
2.4
|
0.7
|
65% |
| 10
|
Zoloft
|
2.2
|
0.7
|
12% |
| |
Total
10 Leading Products |
$34.5
|
10.9%
|
+21%
|
|
Source:
World Review 2001 (*Growth measured in constant US
dollars)
For further details about IMS HEALTH's World Review
2001 please contact Paul Jenner via e-mail at pjenner@uk.imshealth.com.
For full explanation of figures and collection methods
see Data
Value and definitions. |
